<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-7-77</article-id><article-id pub-id-type="pmid">17052327</article-id><article-id pub-id-type="doi">10.1186/1471-2350-7-77</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Rubinstein-Taybi Syndrome: spectrum of <italic>CREBBP </italic>mutations in Italian patients</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Bentivegna</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>angela.bentivegna@unimib.it</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Milani</surname><given-names>Donatella</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>donatella.milani@icp.mi.it</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Gervasini</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cristina.gervasini@unimi.it</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Castronovo</surname><given-names>Paola</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>paola.castronovo@gmail.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Mottadelli</surname><given-names>Federica</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>federica_mottadelli@hotmail.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Manzini</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>heartofwinter@email.it</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Colapietro</surname><given-names>Patrizia</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>patrizia.colapietro@unimi.it</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Giordano</surname><given-names>Lucio</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>pavifan@tin.it</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Atzeri</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>francesca.atzeri@tiscali.it</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Divizia</surname><given-names>Maria T</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>maridiv@tin.it</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Uzielli</surname><given-names>Maria L Giovannucci</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>uzielli_ml@unifi.it</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Neri</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>gneri@rm.unicatt.it</email></contrib><contrib id="A13" contrib-type="author"><name><surname>Bedeschi</surname><given-names>Maria F</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>m.f.bedeschi@icp.mi.it</email></contrib><contrib id="A14" contrib-type="author"><name><surname>Faravelli</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>francesca.faravelli@galliera.it</email></contrib><contrib id="A15" equal-contrib="yes" contrib-type="author"><name><surname>Selicorni</surname><given-names>Angelo</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>ambulatorio@gencli.it</email></contrib><contrib id="A16" equal-contrib="yes" corresp="yes" contrib-type="author"><name><surname>Larizza</surname><given-names>Lidia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lidia.larizza@unimi.it</email></contrib></contrib-group><aff id="I1"><label>1</label>Division of Medical Genetics, San Paolo School of Medicine, University of Milan, Italy</aff><aff id="I2"><label>2</label>I Clinica Pediatrica, Fondazione Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy</aff><aff id="I3"><label>3</label>Department of Biology and Genetics, Medical Faculty, University of Milan, Milan, Italy</aff><aff id="I4"><label>4</label>Neuropsichiatria Infantile, Spedali Civili, Brescia, Italy</aff><aff id="I5"><label>5</label>Laboratory of Molecular Genetics, G. Gaslini Institute, Genova, Italy</aff><aff id="I6"><label>6</label>Department of Paediatrics, Genetics Unit &#x02013; Children's Hospital A. Meyer, Florence, Italy</aff><aff id="I7"><label>7</label>Institute of Medical Genetics, Catholic University, Rome, Italy</aff><aff id="I8"><label>8</label>Servizio di Genetica Medica, Fondazione Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy</aff><aff id="I9"><label>9</label>Department of Human Genetics of Galliera Hospital, Genoa, Italy</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>19</day><month>10</month><year>2006</year></pub-date><volume>7</volume><fpage>77</fpage><lpage>77</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/7/77"/><history><date date-type="received"><day>2</day><month>8</month><year>2006</year></date><date date-type="accepted"><day>19</day><month>10</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Bentivegna et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Bentivegna et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Bentivegna Angela angela.bentivegna@unimib.it </dc:author><dc:title> Rubinstein-Taybi Syndrome: spectrum of CREBBP mutations in Italian patients </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 7(1): 77-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2006)7:1&#x0003c;77&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Rubinstein-Taybi Syndrome (RSTS, MIM 180849) is a rare congenital disorder characterized by mental and growth retardation, broad and duplicated distal phalanges of thumbs and halluces, facial dysmorphisms and increased risk of tumors. RSTS is caused by chromosomal rearrangements and point mutations in one copy of the CREB-binding protein gene (<italic>CREBBP </italic>or <italic>CBP</italic>) in 16p13.3. To date mutations in <italic>CREBBP </italic>have been reported in 56.6% of RSTS patients and an average figure of 10% has ascribed to deletions.</p></sec><sec sec-type="methods"><title>Methods</title><p>Our study is based on the mutation analysis of <italic>CREBBP </italic>in 31 Italian RSTS patients using segregation analysis of intragenic microsatellites, BAC FISH and direct sequencing of PCR and RT-PCR fragments.</p></sec><sec><title>Results</title><p>We identified a total of five deletions, two of the entire gene and three, all in a mosaic condition, involving either the 5' or the 3' region. By direct sequencing a total of 14 de novo mutations were identified: 10 truncating (5 frameshift and 5 nonsense), one splice site, and three novel missense mutations. Two of the latter affect the HAT domain, while one maps within the conserved nuclear receptor binding of (aa 1&#x02013;170) and will probably destroy a Nuclear Localization Signal. Identification of the p.Asn1978Ser in the healthy mother of a patient also carrying a de novo frameshift mutation, questions the pathogenetic significance of the missense change reported as recurrent mutation. Thirteen additional polymorphisms, three as of yet unreported, were also detected.</p></sec><sec><title>Conclusion</title><p>A high detection rate (61.3%) of mutations is confirmed by this Italian study which also attests one of the highest microdeletion rate (16%) documented so far.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Rubinstein-Taybi syndrome (RSTS; MIM 180849) is a congenital disorder characterized by growth retardation and psychomotor developmental delay, broad and duplicated distal phalanges of thumbs and halluces, and a wide range of typical dysmorphic features. Facial dysmorphology includes down-slanted palpebral fissures, broad nasal bridge, beaked nose and micrognathia [<xref ref-type="bibr" rid="B1">1</xref>]. In addition, patients with RSTS have an increased, although not well documented, risk of tumor formation [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. RSTS was shown to be associated with microdeletions and point mutations in the gene encoding the CREB-binding protein (CREBBP, also known as "CBP"), located in 16p13.3 [<xref ref-type="bibr" rid="B4">4</xref>]. CREBBP is a transcriptional coactivator and possesses acetyltransferase activity on lysine residues of histones and nonhistone proteins [<xref ref-type="bibr" rid="B5">5</xref>]. CREBBP partecipates in basic cellular functions, including growth, differentiation, DNA repair and apoptosis, regulating the expression of many genes [<xref ref-type="bibr" rid="B6">6</xref>]. The mutations found in RSTS patients vary from point mutations to relatively large microdeletions, which remove the entire gene, attesting that haploinsufficiency of this dosage-sensitive gene is the ultimate cause of the syndrome. More precisely, studies of patients with missense and splice-site mutations that affect only the histone acetyl transferase (HAT) domain of CREBBP demonstrated that loss of HAT activity is sufficient to cause the syndrome [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. The related p300 protein, which is encoded by the <italic>EP300 </italic>gene on chromosome 22q13.2, shares homology with CREBBP and accordingly serves as a transcriptional coactivator endowed with a HAT domain [<xref ref-type="bibr" rid="B9">9</xref>]. Mutations of EP300 have been recently reported in a small subset (3.3%) of RSTS patients [<xref ref-type="bibr" rid="B10">10</xref>]. This figure and the low detection rates (from 40% to 56.6%) of <italic>CREBBP </italic>gene assessed by all mutations studies of RSTS patients suggest that other candidate genes might contribute to the pathogenesis of this syndrome [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. We recruited 31 patients with consistent RSTS clinical diagnosis and we tested them by microsatellite segregation analysis, FISH, RT-PCR and direct sequencing to find mutations of the <italic>CREBBP </italic>gene. This multimethod approach allowed us to identify five deletions and 14 point mutations, accounting for the highest (61.3%) mutation rate so far assessed. Particularly FISH analysis was instrumental for detecting even subtle microdeletions proving to be a method suitable more than mutation analysis to disclose low level mosaic conditions.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>We analysed samples of 31 unrelated patients sent to our laboratory with parental consent with the request of genetic analysis for Rubinstein-Taybi syndrome. Studies and procedures were in accordance with the ethical standards of the host institutions. The group consisted of 16 female and 15 male patients, aged 2 to 42 years. Clinical diagnoses were established by different Centers and eventually confirmed by the coordinating clinical Center (Dept of Pediatrics, University of Milan) based on clinical records and photographs, when no pathogenetic mutation could be found. Careful examination of the patients' phenotypes was done, and the presence of malformations and medical complications were confirmed or excluded.</p><p>Thirty subjects had a normal karyotype by Giemsa-trypsin banding at 450-band resolution; patient 38 showed a 46, XY, der(14)t(9;14)(p11.2;p11.2) karyotype.</p></sec><sec><title>Cell cultures, chromosome and interphase nuclei preparations</title><p>Phytohemagglutinin-stimulated peripheral blood lymphocytes were set up in culture from samples using Chromosome Kit "Synchro" (Celbio) and modified RPMI (Irvine Scientific) plus 5% fetal calf serum (Gibco). The cultures were blocked with colchicine after 72 h. Chromosome preparations were obtained using a standard technique.</p></sec><sec><title>Clone preparations</title><p>BAC clones RP11 95J11, RP11 461A8 and RP11 566K11 were supplied by Mariano Rocchi [<xref ref-type="bibr" rid="B13">13</xref>]; BAC RP11 1072J2 was purchased from the CHORI BAC PAC Resource Center (Oakland, USA). DNA was obtained starting from a single colony grown in 4 ml of LB medium supplemented with 20 &#x003bc;g/ml chloramphenicol (Sigma) following standard procedures.</p></sec><sec><title>FISH</title><p>BAC clones were labelled with digoxigenin-dUTP (Roche Diagnostic) using a nick translation kit (Roche Diagnostic). The FISH experiments were performed according to standard procedures [<xref ref-type="bibr" rid="B14">14</xref>]. The chromosomes were counterstained with DAPI in antifade (Vectashild), and then visualised using a Leitz DM-RB microscope equipped for DAPI and FITC/TRITC epifluorescence optics. The images were captured by means of a CCD camera (Hamamatsu 3CCD Camera, C5810) and visualised using Highfish software (Casti Imaging).</p></sec><sec><title>Analysis of FISH signals in mosaic condition</title><p>Almost 50 metaphases and 100 nuclei were scored for each sample in order to establish the mosaic condition. Only intact and undamaged nuclei free of cytoplasm were analyzed. Nuclei with low signal intensities, diffuse signals, or absence of signals on both homolog chromosomes were considered to be hybridization failures and were not scored. Two small focal (or paired) signals of the same color and the same intensity, separated by a distance of less than the area of one signal, were considered to be a split signal from one chromosome. Interphase nuclei with one large signal of the same color and increased intensity of fluorescence with the absence of a second hybridization signal in an interphase nucleus were considered to be overlapping (or over-position) of two signals and were not scored. Informative mosaic samples were defined as those in which more than 5% of the nuclei had a reproducible abnormal pattern of signals different from normal chromosomal signals.</p></sec><sec><title>Microsatellite segregation analysis</title><p>Fluorescent genotyping was performed as previously described [<xref ref-type="bibr" rid="B11">11</xref>]. The following fluorescently dye-labeled chromosome 16p microsatellite markers: MS4, MS2 and D16S3065 (from centromere to telomere) were used for segregation analysis from parents to probands. Fluorescence detection was performed on an ABI 3100 sequencer. ABI PRISM software (Genescan) was used for gel analysis.</p></sec><sec><title>RT-PCR analysis</title><p>RT-PCR analysis was performed as previously described [<xref ref-type="bibr" rid="B11">11</xref>] for patients 14, 16, 20, 25, 28 and 29 for whom mRNA was available.</p></sec><sec><title>Molecular analysis</title><p>The DNA sequencing of all coding exons of the <italic>CREBBP </italic>gene was performed as previously described [<xref ref-type="bibr" rid="B11">11</xref>]. Twentysix <italic>CREBBP </italic>PCR genomic fragments were amplified (see <xref ref-type="supplementary-material" rid="S1">Additional file 1</xref>). The DNA sequencing protocol was updated for use with the BigDye Chemistry, Versions 2.0 and 3.1, and the ABI PRISM 310 and 377 Genetic analyzer systems (Applied Biosystems, Darmstadt, Germany). If a mutation or polymorphism was found, a second sequencing run was performed for confirmation. The origin of the mutation or polymorphism, whether <italic>de novo </italic>or familial, was established if parental DNA was available. Paternity testing was not performed due to legal restrictions. The Human Gene Mutation Database (HGMD) [<xref ref-type="bibr" rid="B15">15</xref>], recent publications [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>], and the dbSNP database [<xref ref-type="bibr" rid="B16">16</xref>] were consulted to check whether sequence variations were previously reported or not. Missense mutations of patients 15 and 46 identified in this study were absent in 100 controls, while that carried by patient 23 was absent in 50 controls.</p></sec></sec><sec><title>Results</title><sec><title>Clinical evaluation</title><p>Thirty-one Italian RSTS patients, whose main signs are reported in Table <xref ref-type="table" rid="T1">1</xref>, were carefully clinically analysed. Sex ratio was F:M = 16:15. All patients had psychomotor/mental retardation, which ranged from mild to severe in 17 cases. Microcephaly was evident in 20 (64.5%); a subset (12 cases) accounting for 61.3% of RSTS patients manifested poor growth. The main facial features were specifically described and/or evident from photos (see Figure <xref ref-type="fig" rid="F1">1</xref>) and the overall facial gestalt was absolutely typical in all but one patient. As reported in Table <xref ref-type="table" rid="T1">1</xref>, the typical large thumb was evident in 93% (27/29 patients), and in 11 cases it was also abducted; the hallux was large in 89% (26/29), and only in 4 cases it was valgus/varus. Only 11 individuals had major malformations of internal organs or limbs: congenital heart disease (patent ductus arteriosus, ventricular/atrial septum defects, bicuspid aorta) was reported in 6 of them, cryptorchid testes in 3, coloboma of the optic nerve, renal hypoplasia, duodenal malrotation and hexadactyly in one. In 5 patients supernumerary nipples were evident. Only in two cases (pt 16 and 17) lacrimal ducts stenosis and sensorineural deafness (pt 14 and 38) were signaled. In case 46 the presence of multiple epitheliomas was reported. In another single case (pt 15) Perthe's disease was found.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>a </bold>Patient 16 (negative for <italic>CREBBP </italic>mutations); <bold>b </bold>patient 17 (c.3715_3716delAA in <italic>CREBBP </italic>gene); <bold>c </bold>patient 46 (c.4627G&#x0003e;T in <italic>CREBBP </italic>gene). The typical RSTS facial features are visible in the three patients.</p></caption><graphic xlink:href="1471-2350-7-77-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Main clinical signs of the thirty-one Italian RSTS patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">patient</td><td align="center">age</td><td align="center">sex</td><td align="center">microcephaly</td><td align="center">facial features</td><td align="center">PMR/MR</td><td align="center">large/bifid abducted thumb</td><td align="center">hallux large/bifid</td><td align="center">hallux valgus/varus</td><td align="center">poor growth</td><td align="center">malformations</td><td align="center">CREBBP mutation</td></tr></thead><tbody><tr><td align="center">46*</td><td align="center">3</td><td align="center">F</td><td align="center">-</td><td align="center">+</td><td align="center">+ moderate</td><td align="center">+/-</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">+</td><td align="center">missense</td></tr><tr><td align="center">42</td><td align="center">18</td><td align="center">F</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+/+</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">-</td><td align="center">deletion</td></tr><tr><td align="center">32</td><td align="center">4</td><td align="center">F</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+/-</td><td align="center">+</td><td align="center">+/-</td><td align="center">+</td><td align="center">-</td><td align="center">nonsense</td></tr><tr><td align="center">34</td><td align="center">2</td><td align="center">M</td><td align="center">+</td><td align="center">+</td><td align="center">+ moderate</td><td align="center">+/-</td><td align="center">-</td><td align="center">-/-</td><td align="center">+</td><td align="center">-</td><td align="center">nonsense</td></tr><tr><td align="center">15</td><td align="center">11</td><td align="center">M</td><td align="center">+</td><td align="center">+</td><td align="center">+ severe</td><td align="center">+/-</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">+</td><td align="center">missense</td></tr><tr><td align="center">2</td><td align="center">10</td><td align="center">F</td><td align="center">+</td><td align="center">+</td><td align="center">+ moderate</td><td align="center">+/-</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">-</td><td align="center">insertion</td></tr><tr><td align="center">11</td><td align="center">14</td><td align="center">M</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+/+</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">+</td><td align="center">nonsense</td></tr><tr><td align="center">17</td><td align="center">14</td><td align="center">F</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+/-</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">+</td><td align="center">deletion</td></tr><tr><td align="center">20</td><td align="center">10</td><td align="center">F</td><td align="center">+</td><td align="center">+</td><td align="center">+ severe</td><td align="center">+/-</td><td align="center">+</td><td align="center">-/+</td><td align="center">+</td><td align="center">-</td><td align="center">splice-site mutation</td></tr><tr><td align="center">21</td><td align="center">7</td><td align="center">M</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+/+</td><td align="center">+</td><td align="center">+/+</td><td align="center">-</td><td align="center">+</td><td align="center">deletion</td></tr><tr><td align="center">22</td><td align="center">30</td><td align="center">F</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+/+</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">-</td><td align="center">deletion</td></tr><tr><td align="center">23</td><td align="center">5</td><td align="center">F</td><td align="center">-</td><td align="center">+</td><td align="center">+ moderate</td><td align="center">+/+</td><td align="center">+</td><td align="center">-/-</td><td align="center">-</td><td align="center">+</td><td align="center">missense</td></tr><tr><td align="center">24</td><td align="center">7</td><td align="center">F</td><td align="center">-</td><td align="center">+</td><td align="center">+</td><td align="center">+/-</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">-</td><td align="center">nonsense</td></tr><tr><td align="center">35</td><td align="center">39</td><td align="center">M</td><td align="center">-</td><td align="center">+</td><td align="center">+</td><td align="center">+/-</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">-</td><td align="center">nonsense</td></tr><tr><td align="center">40</td><td align="center">26</td><td align="center">F</td><td align="center">+</td><td align="center">nd</td><td align="center">+ severe</td><td align="center">+/-</td><td align="center">+</td><td align="center">nd</td><td align="center">+</td><td align="center">-</td><td align="center">mosaic del 5'</td></tr><tr><td align="center">66</td><td align="center">6</td><td align="center">M</td><td align="center">-</td><td align="center">+</td><td align="center">+ severe</td><td align="center">+/-</td><td align="center">+</td><td align="center">-</td><td align="center">-</td><td align="center">+</td><td align="center">mosaic del 5'</td></tr><tr><td align="center">41</td><td align="center">25</td><td align="center">F</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+/+</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">-</td><td align="center">del mat</td></tr><tr><td align="center">38</td><td align="center">5</td><td align="center">M</td><td align="center">-</td><td align="center">+</td><td align="center">+ severe</td><td align="center">-/-</td><td align="center">+</td><td align="center">-/-</td><td align="center">-</td><td align="center">-</td><td align="center">mosaic del 3'</td></tr><tr><td align="center">30</td><td align="center">26</td><td align="center">F</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+/+</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">-</td><td align="center">del mat</td></tr><tr><td align="center">36</td><td align="center">11</td><td align="center">F</td><td align="center">-</td><td align="center">+</td><td align="center">+ borderline</td><td align="center">+/-</td><td align="center">-</td><td align="center">-/-</td><td align="center">-</td><td align="center">-</td><td align="center">neg</td></tr><tr><td align="center">39</td><td align="center">13</td><td align="center">M</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">+</td><td align="center">neg</td></tr><tr><td align="center">43</td><td align="center">11</td><td align="center">M</td><td align="center">+</td><td align="center">+</td><td align="center">+ servere</td><td align="center">nd</td><td align="center">nd</td><td align="center">nd</td><td align="center">-</td><td align="center">nd</td><td align="center">neg</td></tr><tr><td align="center">44</td><td align="center">21</td><td align="center">M</td><td align="center">nd</td><td align="center">+</td><td align="center">+</td><td align="center">+/+</td><td align="center">+</td><td align="center">-/-</td><td align="center">-</td><td align="center">-</td><td align="center">neg</td></tr><tr><td align="center">1</td><td align="center">9</td><td align="center">M</td><td align="center">+</td><td align="center">+</td><td align="center">+ moderate</td><td align="center">+/-</td><td align="center">-</td><td align="center">-/-</td><td align="center">-</td><td align="center">-</td><td align="center">neg</td></tr><tr><td align="center">12</td><td align="center">17</td><td align="center">M</td><td align="center">+</td><td align="center">+/-</td><td align="center">+ moderate</td><td align="center">+/-</td><td align="center">+</td><td align="center">-/-</td><td align="center">+</td><td align="center">-</td><td align="center">neg</td></tr><tr><td align="center">14</td><td align="center">6</td><td align="center">F</td><td align="center">-</td><td align="center">+</td><td align="center">+ moderate</td><td align="center">+/+</td><td align="center">+</td><td align="center">-/-</td><td align="center">-</td><td align="center">+</td><td align="center">neg</td></tr><tr><td align="center">16</td><td align="center">8</td><td align="center">M</td><td align="center">+</td><td align="center">+</td><td align="center">+ moderate</td><td align="center">+/+</td><td align="center">+</td><td align="center">-/+</td><td align="center">+</td><td align="center">+</td><td align="center">neg</td></tr><tr><td align="center">25</td><td align="center">4</td><td align="center">M</td><td align="center">-</td><td align="center">+</td><td align="center">+ mild</td><td align="center">+/-</td><td align="center">+</td><td align="center">-/-</td><td align="center">-</td><td align="center">+</td><td align="center">neg</td></tr><tr><td align="center">45</td><td align="center">28</td><td align="center">F</td><td align="center">nd</td><td align="center">+</td><td align="center">+ moderate</td><td align="center">nd</td><td align="center">nd</td><td align="center">nd</td><td align="center">+</td><td align="center">nd</td><td align="center">neg</td></tr><tr><td align="center">28</td><td align="center">42</td><td align="center">F</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+/+</td><td align="center">+</td><td align="center">-/-</td><td align="center">-</td><td align="center">-</td><td align="center">neg</td></tr><tr><td align="center">29</td><td align="center">37</td><td align="center">M</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+/-</td><td align="center">+</td><td align="center">-/-</td><td align="center">-</td><td align="center">-</td><td align="center">neg</td></tr></tbody></table><table-wrap-foot><p>*development of multiple epiteliomas</p></table-wrap-foot></table-wrap></sec><sec><title>Mutation analysis</title><p>We screened the 31 recruited patients for point mutations, small deletions or insertions, and large deletions and duplications of the <italic>CREBBP </italic>gene. First, by genotyping the polymorphic intragenic repeats MS4, MS2 and D16S3065 [<xref ref-type="bibr" rid="B11">11</xref>] plus one SNP (c.5454G&#x0003e;A, [<xref ref-type="bibr" rid="B12">12</xref>]) we could identify two deletions spanning the whole gene in patients 30 and 41. Both deletions affected the maternal chromosome. Figure <xref ref-type="fig" rid="F2">2</xref> shows for patient 30: (A) the haplotype reconstruction attesting the lack of three maternally contributed intragenic polymorphic loci; (B) FISH of the <italic>CREBBP </italic>spanning BAC 1072J2 evidencing a signal of reduced intensity on one chromosome 16. By means of FISH analysis we detected three additional deletions, all in a mosaic condition. Two (pt 40, pt 66) affect the 5' of the gene, while one (pt 38), spans mainly the central region of the gene and its flanking 3' sequences. The last one is present in a structurally rearranged karyotype (see <italic>subjects </italic>in the methods section). The mosaic condition has been confirmed in two patients from which buccal smears were available. Scoring of <italic>CREBBP </italic>specific signals on both lymphocytes (&#x0003e; 150 cells- metaphases and nuclei) and buccal smears (&#x0003e;100 nuclei) gave comparable results in showing an average 20% of deleted cells in both cases. A fraction of 30% deleted cells was estimated on the third case for whom a sample of 300 cells from peripheral blood was scored. Current studies are in progress aimed to evaluating the extent and boundaries of all the deletions. These data will be reported elsewhere. A schematic view of the identified deletions mapped on the encompassed genomic <italic>CREBBP </italic>region is shown in Figure <xref ref-type="fig" rid="F3">3</xref>.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><italic>CREBBP </italic>deletion in patient 30 detected through: <bold>a </bold>genotyping of intragenic polymorphic markers (MS4, MS2, D16S3065 and SNP c.5454G&#x0003e;A) in the available family members allowing haplotype reconstruction; <bold>b </bold>Double color FISH analysis showing a signal of highly reduced intensity on one chromosome 16p for BAC 1072J2, specific for <italic>CREBBP </italic>(in red). The residual hybridization is accounted for by the size of the genomic clone higher than the deleted region. The control subtelomeric 16q BAC 566K11 shows a comparable signal on both chromosomes (in green).</p></caption><graphic xlink:href="1471-2350-7-77-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Mapping of the five deletions on the <italic>CREBBP </italic>genomic region. Top: genomic organization of <italic>CREBBP </italic>with exons represented by black boxes and introns as connecting lines. The intragenic polymorphic loci are positioned across the gene. Middle: BAC clones used for preliminary FISH analysis, indicated by bars. Bottom: deletions are shown by thick lines; deletion ends containing the breakpoints, are represented by dashed lines.</p></caption><graphic xlink:href="1471-2350-7-77-3"/></fig><p>Then we screened the remaining 26 patients for point mutations by direct sequencing of 26 PCR genomic fragments encompassing the complete coding sequence and splice sites of <italic>CREBBP</italic>. We identified 14 sequence alterations of pathogenic significance: all are listed in Table <xref ref-type="table" rid="T2">2</xref> and shown in Figure <xref ref-type="fig" rid="F4">4</xref> in their location within exons encoding different CREBBP domains. Although the identified mutations are distributed across the whole gene without apparent hot-spots, six, including two missense (p.Tyr1482Cys; p.Asp1543Tyr), and four truncating mutations (p.Lys1239ValfsX14; p.Gly1479X; p.Asp1543GlnfsX39; p.Pro1655CysfsX89) are clustered within the HAT domain. Out of the remaining mutations, which map outside the HAT domain, five of eight are predicted to lead to premature translation stops upstream of the HAT region, thus indirectly spoiling its function. They comprise p.Arg370X and p.Arg424X in the N-Terminal Transactivation Domain (TAD), p.Gln662X in the CREB Binding Domain and p.Gln1118ProfsX13 and p.Arg1173X in the Bromodomain. The remaining three mutations, p.Arg14Gly in the 5' Nuclear Receptor Binding Domain, p.Ser2015AlafsX25 and p.Gln2022ArgfsX16 in the C-Terminal TAD, do not affect the HAT domain at all.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Fourteen causative CREBBP mutations detected by direct sequencing.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">PATIENT</td><td align="center">MUTATION</td><td align="center">TYPE</td></tr></thead><tbody><tr><td align="center">23</td><td align="left">Ex 1: c.40 A&#x0003e;G &#x02013; p.Arg14Gly</td><td align="center">missense</td></tr><tr><td align="center">24</td><td align="left"><italic>Ex 4: c.1108C&#x0003e;T &#x02013; p.Arg370X (Bartsch et al.2002)</italic></td><td align="center">nonsense</td></tr><tr><td align="center">35</td><td align="left"><italic>Ex 5: c.1270C&#x0003e;T &#x02013; p.Arg424X (Bartsch et al.2005)</italic></td><td align="center">nonsense</td></tr><tr><td align="center">11</td><td align="left">Ex 10: c.1984C&#x0003e;T &#x02013; p.Gln662X</td><td align="center">nonsense</td></tr><tr><td align="center">2</td><td align="left">Ex 17: c.3351_3352dupCC &#x02013; p.Gln1118ProfsX13</td><td align="center">insertion</td></tr><tr><td align="center">32</td><td align="left">Ex 18: c.3517C&#x0003e;T &#x02013; p.Arg1173X</td><td align="center">nonsense</td></tr><tr><td align="center">17</td><td align="left">Ex 20: c.3715_3716delAA &#x02013; p.Lys1239ValfsX14</td><td align="center">deletion</td></tr><tr><td align="center">34</td><td align="left">Ex 27: c.4435G&#x0003e;T &#x02013; p.Gly1479X</td><td align="center">nonsense</td></tr><tr><td align="center">15</td><td align="left">Ex 27: c.4445A&#x0003e;G &#x02013; p.Tyr1482Cys</td><td align="center">missense</td></tr><tr><td align="center">46</td><td align="left">Ex 28: c.4627G&#x0003e;T &#x02013; p.Asp1543Tyr</td><td align="center">missense</td></tr><tr><td align="center">20</td><td align="left">Ex 28: c.4728+1G&#x0003e;A</td><td align="center">splice-site mutation</td></tr><tr><td align="center">22</td><td align="left">Ex 30: c.4963delC &#x02013; p.Leu1655CysfsX89</td><td align="center">deletion</td></tr><tr><td align="center">42</td><td align="left">Ex 31: c.6043delA &#x02013; p.Ser2015AlafsX25</td><td align="center">deletion</td></tr><tr><td align="center">21</td><td align="left">Ex 31: c.6065_6071delAGCAGGC &#x02013; p.Gln2022AgfsX16</td><td align="center">deletion</td></tr></tbody></table><table-wrap-foot><p>In italics: mutations previously described.</p></table-wrap-foot></table-wrap><fig position="float" id="F4"><label>Figure 4</label><caption><p>Location of the 14 causative CREBBP mutations found in this study. Only exons are drawn to scale. The histone acetyl transferase domain and the plant homeodomain (PHD)-type zinc finger are indicated according to Kalkhoven et al. (2003), other domains according to Giles et al. (1997). Truncating mutations are in light-grey, missense mutations in dark-grey and the two previously reported mutations in italics.</p></caption><graphic xlink:href="1471-2350-7-77-4"/></fig><p>Twelve of 14 mutations are novel, while p.Arg370X has been reported by several groups [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B17">17</xref>] and p.Arg424X has been also recently described [<xref ref-type="bibr" rid="B12">12</xref>]. As to the nine different single nucleotide substitutions they consist of five nonsense (pts 24, 35, 11, 32 and 34), three missense (pts 23, 15 and 46) and one splice site mutation (patient 20). Out of the five sequence alterations producing a frameshift in the reading frame, one is a 2 bp-duplication (pt 2) leading to the potential incorporation of 12 anomalous aminoacids, three are deletions sized 1, 2 and 7 nucleotides respectively (pts 22, 17 and 21) predicting 88, 13 and 15 anomalous aminoacids and one is a splice site mutation (c.4728+1G&#x0003e;A) affecting IVS 28 donor site. Analysis of this mutation with two different softwares, the Splice Site Prediction by Neural Network (BDGP) [<xref ref-type="bibr" rid="B18">18</xref>] and the SpliceView [<xref ref-type="bibr" rid="B19">19</xref>] indicated that the splice donor site was suppressed (predicted scores = 0%) and a novel candidate donor site 260 bp upstream the mutation was activated. The SpliceView software, also detected a near donor site, 104 bp upstream the splice mutation. We were able to identify <italic>CREBBP </italic>transcripts from patient 20 also including a smaller transcript, in addition to the normal one (Figure <xref ref-type="fig" rid="F5">5</xref>). Direct sequencing of the anomalous transcript confirmed the activation of the nearest upstream cryptic donor site predicted by the SpliceView software. The frameshift produced by missplicing should lead to the incorporation of 38 anomalous aminoacids.</p><fig position="float" id="F5"><label>Figure 5</label><caption><p>RT-PCR and bioinformatic analysis of the splice site mutation (c.4728+1G&#x0003e;A) of pt 20. <bold>a </bold>RT-PCR of the CREBBP fragment including Ex 28 and 29 evidenced an additional smaller fragment (NC: normal control). <bold>b </bold>bioinformatic analysis with Splice Site Prediction [18] and the SpliceView [19]: the physiological donor site is in bold; the <italic>de-novo </italic>donor site activated is underscored. <bold>c </bold>schematic diagram of the misplicing predicted to occur in this patient with the cryptic donor site underscored. On the left electropherogram of the normal donor site; on the right the electropherogram attesting activation of the cryptic donor site.</p></caption><graphic xlink:href="1471-2350-7-77-5"/></fig><p>All three missense changes, p.Arg14Gly (pt 23), p.Asp1543Tyr (pt 46) and p.Tyr1482Cys (pt 15) were not previously reported. They were established to have occurred <italic>de novo </italic>and were found absent in 50 (p.Arg14Gly) and in 100 (p.Asp1543Tyr and p.Tyr1482Cys) healthy individuals, respectively. Furthermore all of them affect aminoacids that are highly conserved both through evolution and in the related p300 (Figure <xref ref-type="fig" rid="F6">6</xref>) [<xref ref-type="bibr" rid="B20">20</xref>]. p.Arg14Gly in the 5' Nuclear Receptor Binding Domain is predicted by PSORTII [<xref ref-type="bibr" rid="B21">21</xref>] to cause the destruction of a monopartite Nuclear Localization Sequence (NLS) (Figure <xref ref-type="fig" rid="F7">7</xref>). This NLS is a typical monopartite cluster of basic residues, with a conserved pattern starting with Pro, followed by Lys or Arg in 3 out of 5 residues (PKRAKLS) [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. In addition the same software predicted another central bipartite Nuclear Localization Signal at 1591 (KKTNKNKSSISRANKKK). Both the NLSs are highly conserved in mouse CREBBP and in p300 protein. p.Tyr1482Cys and the p.Asp1543Tyr are both in the HAT domain. Finally we detected 18 CREBBP polymorphisms, including 12 single nucleotide polymorphisms (SNPs) and a 3'UTR 1 bp-duplication (see <xref ref-type="supplementary-material" rid="S2">Additional file 2</xref>). Three of the sequence variations have not been previously reported, including two intronic SNPs (c.3983-22C&#x0003e;T, c.4560+14A&#x0003e;G) and the 3'UTR 7329+25dupC. Conversely the sequence variation (c.5933A&#x0003e;G), was reported in other patients with RSTS [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. This substitution, causing the p.Asn1978Ser change in a conserved glutamine-rich region, downstream the HAT domain, has been inherited by our patient 22 by his apparently normal mother. The same patient was found to bear a <italic>de novo </italic>truncating mutation in the exon upstream the p.Asn1978Ser change (c.4963delC). We were able to establish that both mutations occurred on the maternal allele in a cis configuration (data not shown). Moreover we detected the same nucleotide substitution in one of 50 controls analysed.</p><fig position="float" id="F6"><label>Figure 6</label><caption><p>Conservation of amino acids that are predicted by ClustalW [20] to change by three missense mutations identified in this study. <bold>a </bold>p.Arg14Gly of pt 23; <bold>b </bold>p.Tyr1482Cys of pt 15; <bold>c </bold>p.Asp1543Tyr of pt 46. The changed residues are conserved in man (GeneBank: Q92793), in mouse (GeneBank: P45481), in <italic>Drosophila melanogaster </italic>(DROM3A), in <italic>Caenorabditis elegans </italic>(CEL116) and in P300 protein.</p></caption><graphic xlink:href="1471-2350-7-77-6"/></fig><fig position="float" id="F7"><label>Figure 7</label><caption><p>Nuclear Localization signals (NLSs) predicted by PSORTII [21] analysis. <bold>a </bold>wild-type CREBBP with three putative NLSs (two monopartite and one bipartite) evidenced by squares: the affected Arg14 is marked in red; <bold>b </bold>Mutated CREBBP of patient 23 with Arg14Gly substitution with only one predicted NLS. The bottom panels show the cellular localization predictions of wt and mutated proteins.</p></caption><graphic xlink:href="1471-2350-7-77-7"/></fig></sec></sec><sec><title>Discussion</title><p>By investigating 31 RSTS Italian patients using approaches suitable to detect most types of <italic>CREBBP </italic>mutations we identified <italic>bona fide </italic>causative lesions in 19 subjects (61.3%), a score slightly higher than that recently reported [<xref ref-type="bibr" rid="B12">12</xref>]. Complementary application of FISH and microsatellite analysis allowed us to detect five microdeletions, (which refined FISH characterization will be published elsewhere) one of the highest microdeletion rate (16%) documented so far, a finding that emphasizes possible underestimation of <italic>CBP </italic>microdeletions in RSTS patients [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. Data achieved using realtime quantitative PCR are consistent with this view [<xref ref-type="bibr" rid="B27">27</xref>].</p><p>Interestingly this is the first report describing mosaicism for <italic>CREBBP </italic>deletions, indicating the contribution of mitotic errors to this rare syndrome, that might exploit the same breakpoints of the highly unstable region around intron 2 of <italic>CREBBP </italic>evidenced in cancer [<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B30">30</xref>]. It should be noted that in one case (pt 38) the <italic>CREBBP </italic>mosaic deletion is in the context of a rearranged karyotype, which may account for the complex phenotype of the patient.</p><p>By sequencing all exons and splice sites of the <italic>CREBBP </italic>gene, we identified on a total of 26 patients 14 different mutations, only two of which have been described [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Neither a predominant type of mutation nor clustering of mutations within the <italic>CREBBP </italic>gene are apparent. In agreement with previous studies, most mutations (11/14, &#x0003e;78%) predict premature stop codons [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. Since RSTS is an autosomal dominant trait, it can be assumed that truncating mutations are disease causing mutations making superfluous to determine their <italic>de novo </italic>origin [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. We also detected three putative missense mutations, in which the pathogenic role is much less clear. However, we were able to confirm the <italic>de novo </italic>origin of all three missense mutations which were found only once among 26 patients analysed and were never observed in a 100 normal controls (50 in the case of patient 23), ruling out that they are unreported CBP polymorphisms. Moreover, when compared with the murine CREBBP (Genbank: <ext-link ext-link-type="gen" xlink:href="S66385">S66385</ext-link>) [<xref ref-type="bibr" rid="B31">31</xref>], which shows 95% identity across the whole 2441 aa length of the protein, all the three mutated residues were conserved (Figre <xref ref-type="fig" rid="F6">6</xref>). More generally their conservation, both phylogenetic, from <italic>fruit fly </italic>to <italic>C. Elegans</italic>, and in the related p300 protein highlights the functional importance of these residues in the protein. Interestingly, two missense mutations are in the HAT domain of CREBBP, where similar mutations were shown to be sufficient to cause the RSTS phenotype as they destroyed the acetyltransferase activity [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Furthermore p.Tyr1482Cys (patient 15) is in the postulated coenzyme A binding site (aminoacids 1459&#x02013;1541). It may not be fortuitous that the phenotypic presentation of this patient strikingly overlaps the clinical presentation of a second patient (20), carrying a splicing mutation affecting the same domain. Application of RT-PCR allowed to document the deleterious consequence of the splicing mutation and to better interpret the patient's phenotype. Indeed both patients 15 and 20 are affected by severe mental retardation and complete absence of speech. The third missense mutation, p.Arg14Gly, found in patient 23, is localised in the 5' end of the CREBBP protein, where no other missense mutation has been reported. Aminoacids from 1 to 100 are known to be responsible for the Nuclear-Receptors binding (RAR, GR TXR) [<xref ref-type="bibr" rid="B32">32</xref>]. Moreover, according to the PSORTII software the resulting aminoacid change is predicted to disrupt a putative Nuclear Localization Signal. Functional studies of this mutant protein are in progress to determine whether the predicted NLS is necessary for the correct import of the protein into the nucleus. It should be noted that patient 23 has a mild phenotype, characterised by normal growth and absence of microcephaly. This peculiar phenotype might be accounted for by a reduced amount of CREBBP protein in the nucleus because of impaired translocation of the mutated product, rather than by a reduced binding to Nuclear-Receptors.</p><p>In this study we detected the c.5933A&#x0003e;G leading to p.Asn1978Ser change in patient 22, who carries also a <italic>de novo </italic>truncating mutation (c.4963delC). We were able to establish the cis phase of the two alterations on the maternal allele. The same p.Asn1978Ser change was found in a classic RSTS patient [<xref ref-type="bibr" rid="B11">11</xref>] and has been recently described as a recurrent mutation, in a patient displaying an incomplete RSTS phenotype [<xref ref-type="bibr" rid="B12">12</xref>]. We detected the same change in our patient 22's healthy mother, and subsequently in one of 50 additional control individuals who were studied: thus we infer it may be counted among CREBBP polymorphisms. Consistent with this view, the resulting amino acid substitution, located outside the HAT domain, affects an aminoacidic residue conserved in the mouse, but not either in <italic>fruit fly </italic>and <italic>C. Elegans</italic>, or in p300 (Figure <xref ref-type="fig" rid="F6">6</xref>). Interestingly, a different change of the same residue (p.Asn1978Asp) has been recently detected in an ovarian and a breast tumour from unrelated individuals. Mutation analysis in germline DNA which could be performed on one of the two individuals showed the same sequence alteration present in the tumours [<xref ref-type="bibr" rid="B33">33</xref>]. The authors emphasised that the individual carrying the mutation in the germline does not have the RSTS phenotype, as expected of someone with a <italic>CREBBP </italic>mutation. All the cumulated evidences indicate the affected <italic>CREBBP </italic>codon as a highly polymorphic site, resulting in a aminoacidic change which does not disrupt protein function sufficiently to cause RSTS or to predispose to breast and/or ovarian cancer. The overall data might help to interpret this sequence change and to keep it into account in genetic counselling.</p><p>Finally, we identified 13 additional sequence variations, which can be added to the list of known CREBBP polymorphisms (see <xref ref-type="supplementary-material" rid="S2">Additional file 2</xref>). Interestingly our patients 16 and 25 share five different polymorphisms inherited from their parents, in agreement with a recent report [<xref ref-type="bibr" rid="B12">12</xref>]. Also our two families do not appear to be related, but extended genetic histories were not available.</p></sec><sec><title>Conclusion</title><p>By combining different techniques we identified a <italic>CREBBP </italic>mutation in 61.3% of RSTS cases, a mutation rate higher than that of a recent study [<xref ref-type="bibr" rid="B12">12</xref>]. Intragenic microsatellite markers and FISH analysis enabled us to identify one of the highest microdeletion rate (16%) documented so far [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B34">34</xref>]. No significant correlation could be established between different types of mutation and the clinical presentation and significantly, the patients proved negative to <italic>CREBBP </italic>mutation screening (both point mutations and deletions) represented the whole RSTS phenotypic spectrum. The overall mutation rate attested by our study and the fact that most <italic>CREBBP</italic>-negative patients did not display a mild or borderline RSTS clinical presentation provide further indirect evidence on the involvement of genes other than <italic>CREBBP </italic>in the RSTS phenotype. Indeed, a few <italic>CREBBP </italic>lesions might have been underestimated, as we ruled out silent exonic alterations affecting splicing enhancers (in the <italic>CREBBP</italic>-negative patients 14, 16, 25, 28 and 29), but not intronic alterations affecting splicing as analysis at the RNA level was precluded. Similarly the <italic>CREBBP </italic>promoter could not be tested, as direct sequencing was attempted, but raised technical problems. However the putatively missed <italic>CREBBP </italic>alterations likely do not cover the whole fraction of negative cases with a consistent RSTS phenotype. It may be that a few of the screened patients will turn out, upon a closer clinical examination, to have a different syndrome that resembles RSTS. However, considering the larger set of RSTS patients cumulatively ascertained by other groups, yet mutations were not found in more than half their patients as well [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. The recent finding of only three mutations of the CREBBP homologue p300 in a series of 91 patients did not prompt us to screen this gene in our much more restricted cohort [<xref ref-type="bibr" rid="B10">10</xref>]. However genetic heterogeneity of RSTS patients is documented and lesions in other genes encoding for proteins that interact with CREBBP in various signal transduction pathways, should be considered.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>AB: main investigator with a direct and coordinating role in experimental work; drafted the manuscript and approved the final version of it.</p><p>DM: involved in the collection and critical review of clinical data</p><p>CG, PC, FM: performed laboratory investigation concerning both mutation analysis and FISH screening and helped to draft the manuscript</p><p>SM e PC: involved in the set up of the mutation screening</p><p>LG, FA, MTD, MLGU, GN, MFB, FF: clinical geneticists providing selected patients with RSTS</p><p>AS: supervisor for patients recruitment and clinical diagnosis</p><p>LL: involved in design and coordination of the experimental work; drafted the manuscript and approved the final version of it.</p><p>All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/7/77/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>Additional Table I. Twentysix CREBBP PCR pairs of primer for DNA sequencing of all coding exons of the CREBBP gene, as previously described by Coupry et al. 2002</p></caption><media xlink:href="1471-2350-7-77-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p>Additional Table II. Thirteen CREBBP polymorphisms detected by direct sequencing. The yet unreported variations are bolded.</p></caption><media xlink:href="1471-2350-7-77-S2.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>We would like to thank the patients and their families for contributing to this study, and our clinical colleagues for referring patients and clinical data, especially Dr Emanuela Lucci-Cordisco (Institute of Medical Genetics, Catholic University, Rome, Italy, pt 40); Dr Alice Pessagno (Department of Infantile Neuropsychiatry, G. Gaslini Children's Research Hospital, Genova, Italy, pt 38); Dr Giovanna Olioso (Divisione di Neuropsichiatria Infantile, Spedali Civili, Brescia, Italy, pt 23). The parents of the children depicted in Figure <xref ref-type="fig" rid="F1">1</xref> have provided consent for the use of the images for publication. This work was supported by a grant from ASM (Associazione Italiana Studio Malformazioni).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubinstein</surname><given-names>JH</given-names></name><name><surname>Taybi</surname><given-names>H</given-names></name></person-group><article-title>Broad thumbs and toes and facial abnormalities</article-title><source>Am J Dis Child</source><year>1963</year><volume>105</volume><fpage>588</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">13983033</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>RW</given-names></name><name><surname>Rubinstein</surname><given-names>JH</given-names></name></person-group><article-title>Tumors in Rubinstein-Taybi Syndrome</article-title><source>Am J Med Genet</source><year>1995</year><volume>56</volume><fpage>112</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7747773</pub-id><pub-id pub-id-type="doi">10.1002/ajmg.1320560125</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siraganian</surname><given-names>PA</given-names></name><name><surname>Rubinstein</surname><given-names>JH</given-names></name><name><surname>Miller</surname><given-names>RW</given-names></name></person-group><article-title>Keloids and neoplasms in the Rubinstein-Taybi Syndrome</article-title><source>Med Pediatr Oncol</source><year>1989</year><volume>17</volume><fpage>485</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">2586363</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petrij</surname><given-names>F</given-names></name><name><surname>Giles</surname><given-names>RH</given-names></name><name><surname>Dauwerse</surname><given-names>HG</given-names></name><name><surname>Saris</surname><given-names>JJ</given-names></name><name><surname>Hennekam</surname><given-names>RC</given-names></name><name><surname>Masuno</surname><given-names>M</given-names></name><name><surname>Tommerup</surname><given-names>N</given-names></name><name><surname>van Ommen</surname><given-names>GJ</given-names></name><name><surname>Goodman</surname><given-names>RH</given-names></name><name><surname>Peters</surname><given-names>DJ</given-names></name><etal></etal></person-group><article-title>Rubinstein-Taybi syndrome is caused by mutations in the transcriptional co-activator CBP</article-title><source>Nature</source><year>1995</year><volume>376</volume><fpage>348</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">7630403</pub-id><pub-id pub-id-type="doi">10.1038/376348a0</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bannister</surname><given-names>AJ</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><article-title>The CBP coactivator is a histone acetyltransferase</article-title><source>Nature</source><year>1996</year><volume>384</volume><fpage>641</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">8967953</pub-id><pub-id pub-id-type="doi">10.1038/384641a0</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>RH</given-names></name><name><surname>Smolik</surname><given-names>S</given-names></name></person-group><article-title>CBP/p300 in cell growth, transformation, and development</article-title><source>Genes Dev</source><year>2000</year><volume>14</volume><fpage>1553</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">10887150</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murata</surname><given-names>T</given-names></name><name><surname>Kurokawa</surname><given-names>R</given-names></name><name><surname>Krones</surname><given-names>A</given-names></name><name><surname>Tatsumi</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>M</given-names></name><name><surname>Taki</surname><given-names>T</given-names></name><name><surname>Masuno</surname><given-names>M</given-names></name><name><surname>Ohashi</surname><given-names>H</given-names></name><name><surname>Yanagisawa</surname><given-names>M</given-names></name><name><surname>Rosenfeld</surname><given-names>MG</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name></person-group><article-title>Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome</article-title><source>Hum Mol Genet</source><year>2001</year><volume>10</volume><fpage>1071</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">11331617</pub-id><pub-id pub-id-type="doi">10.1093/hmg/10.10.1071</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalkhoven</surname><given-names>E</given-names></name><name><surname>Roelfsema</surname><given-names>JH</given-names></name><name><surname>Teunissen</surname><given-names>H</given-names></name><name><surname>den Boer</surname><given-names>A</given-names></name><name><surname>Ariyurek</surname><given-names>Y</given-names></name><name><surname>Zantema</surname><given-names>A</given-names></name><name><surname>Breuning</surname><given-names>MH</given-names></name><name><surname>Hennekam</surname><given-names>RC</given-names></name><name><surname>Peters</surname><given-names>DJ</given-names></name></person-group><article-title>Loss of <italic>CBP </italic>acetyltransferase activity by PHD finger mutations in Rubinstein-Taybi syndrome</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><fpage>441</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">12566391</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddg039</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lundblad</surname><given-names>JR</given-names></name><name><surname>Kwok</surname><given-names>RP</given-names></name><name><surname>Laurance</surname><given-names>ME</given-names></name><name><surname>Harter</surname><given-names>ML</given-names></name><name><surname>Goodman</surname><given-names>RH</given-names></name></person-group><article-title>Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator <italic>CBP</italic></article-title><source>Nature</source><year>1995</year><volume>374</volume><fpage>85</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">7870179</pub-id><pub-id pub-id-type="doi">10.1038/374085a0</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roelfsema</surname><given-names>JH</given-names></name><name><surname>White</surname><given-names>SJ</given-names></name><name><surname>Ariyurek</surname><given-names>Y</given-names></name><name><surname>Bartholdi</surname><given-names>D</given-names></name><name><surname>Niedrist</surname><given-names>D</given-names></name><name><surname>Papadia</surname><given-names>F</given-names></name><name><surname>Bacino</surname><given-names>CA</given-names></name><name><surname>den Dunnen</surname><given-names>JT</given-names></name><name><surname>van Ommen</surname><given-names>GJ</given-names></name><name><surname>Breuning</surname><given-names>MH</given-names></name><name><surname>Hennekam</surname><given-names>RC</given-names></name><name><surname>Peters</surname><given-names>DJ</given-names></name></person-group><article-title>Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the <italic>CBP </italic>and EP300 genes can cause disease</article-title><source>Am J Hum Genet</source><year>2005</year><volume>76</volume><fpage>572</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">15706485</pub-id><pub-id pub-id-type="doi">10.1086/429130</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coupry</surname><given-names>I</given-names></name><name><surname>Roudaut</surname><given-names>C</given-names></name><name><surname>Stef</surname><given-names>M</given-names></name><name><surname>Delrue</surname><given-names>MA</given-names></name><name><surname>Marche</surname><given-names>M</given-names></name><name><surname>Burgelin</surname><given-names>I</given-names></name><name><surname>Taine</surname><given-names>L</given-names></name><name><surname>Cruaud</surname><given-names>C</given-names></name><name><surname>Lacombe</surname><given-names>D</given-names></name><name><surname>Arveiler</surname><given-names>B</given-names></name></person-group><article-title>Molecular analysis of the <italic>CBP </italic>gene in 60 patients with Rubinstein-Taybi syndrome</article-title><source>J Med Genet</source><year>2002</year><volume>39</volume><fpage>415</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">12070251</pub-id><pub-id pub-id-type="doi">10.1136/jmg.39.6.415</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartsch</surname><given-names>O</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Richter</surname><given-names>M</given-names></name><name><surname>Morlot</surname><given-names>S</given-names></name><name><surname>Seemanova</surname><given-names>E</given-names></name><name><surname>Wiebe</surname><given-names>G</given-names></name><name><surname>Rasi</surname><given-names>S</given-names></name></person-group><article-title>DNA sequencing of <italic>CREBBP </italic>demonstrates mutations in 56% of patients with Rubistein-Taybi syndrome (RSTS) and in another patients with incomplete RSTS</article-title><source>Hum Genet</source><year>2005</year><volume>117</volume><fpage>485</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16021471</pub-id><pub-id pub-id-type="doi">10.1007/s00439-005-1331-y</pub-id></citation></ref><ref id="B13"><citation citation-type="other"><article-title>Resources for Molecular Cytogenetics</article-title><ext-link ext-link-type="uri" xlink:href="http://www.biologia.uniba.it/rmc/"/></citation></ref><ref id="B14"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Cremer</surname><given-names>T</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Rooney DE, Czepulkowski BH</surname></name></person-group><article-title>Chromosome analysis by non-isotopic in situ hybridization</article-title><source>Human cytogenetics: a practical approach</source><year>1992</year><volume>1</volume><edition>2</edition><publisher-name>IRL, Oxford</publisher-name><fpage>157</fpage><lpage>192</lpage></citation></ref><ref id="B15"><citation citation-type="other"><article-title>HGMD Home Page</article-title><ext-link ext-link-type="uri" xlink:href="http://www.hgmd.cf.ac.uk/ac/index.php"/></citation></ref><ref id="B16"><citation citation-type="other"><article-title>dbSNP Home Page</article-title><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/"/></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartsch</surname><given-names>O</given-names></name><name><surname>Locher</surname><given-names>K</given-names></name><name><surname>Meinecke</surname><given-names>P</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name><name><surname>Seemanova</surname><given-names>E</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Ostermann</surname><given-names>K</given-names></name><name><surname>Rodel</surname><given-names>G</given-names></name></person-group><article-title>Molecular studies in 10 cases of Rubinstein-Taybi syndrome, including a mild variant showing a missense mutation in codon 1175 of CREBBP</article-title><source>J Med Genet</source><year>2002</year><volume>39</volume><fpage>415</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">12070251</pub-id><pub-id pub-id-type="doi">10.1136/jmg.39.7.496</pub-id></citation></ref><ref id="B18"><citation citation-type="other"><article-title>Splice Site Prediction</article-title><ext-link ext-link-type="uri" xlink:href="http://www.fruitfly.org/seq_tools/splice.html"/></citation></ref><ref id="B19"><citation citation-type="other"><article-title>SpliceView</article-title><ext-link ext-link-type="uri" xlink:href="http://l25.itba.mi.cnr.it/~webgene/wwwspliceview.html"/></citation></ref><ref id="B20"><citation citation-type="other"><article-title>ClustalW</article-title><ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/clustalw/"/></citation></ref><ref id="B21"><citation citation-type="other"><article-title>PSORTII</article-title><ext-link ext-link-type="uri" xlink:href="http://psort.ims.u-tokyo.ac.jp/"/></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>K</given-names></name><name><surname>Kanehisa</surname><given-names>M</given-names></name></person-group><article-title>A knowledge base for predicting protein localization sites in eukaryotic cells</article-title><source>Genomics</source><year>1992</year><volume>14</volume><fpage>897</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">1478671</pub-id><pub-id pub-id-type="doi">10.1016/S0888-7543(05)80111-9</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hicks</surname><given-names>GR</given-names></name><name><surname>Raikhel</surname><given-names>NV</given-names></name></person-group><article-title>Protein import into the nucleus: an integrated view</article-title><source>Annu Rev Cell Dev Biol</source><year>1995</year><volume>11</volume><fpage>155</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">8689555</pub-id><pub-id pub-id-type="doi">10.1146/annurev.cb.11.110195.001103</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartsch</surname><given-names>O</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Hinkel</surname><given-names>GK</given-names></name><name><surname>Krebs</surname><given-names>P</given-names></name><name><surname>Stumm</surname><given-names>M</given-names></name><name><surname>Schmalenberger</surname><given-names>B</given-names></name><name><surname>Bohm</surname><given-names>S</given-names></name><name><surname>Balci</surname><given-names>S</given-names></name><name><surname>Majewski</surname><given-names>F</given-names></name></person-group><article-title>FISH studies in 45 patients with Rubinstein-Taybi syndrome: deletions associated with polysplenia, hypoplastic left heart and death in infancy</article-title><source>Eur J Hum Genet</source><year>1999</year><volume>7</volume><fpage>748</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">10573006</pub-id><pub-id pub-id-type="doi">10.1038/sj.ejhg.5200378</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petrij</surname><given-names>F</given-names></name><name><surname>Dauwerse</surname><given-names>HG</given-names></name><name><surname>Blough</surname><given-names>RI</given-names></name><name><surname>Giles</surname><given-names>RH</given-names></name><name><surname>van der Smagt</surname><given-names>JJ</given-names></name><name><surname>Wallerstein</surname><given-names>R</given-names></name><name><surname>Maaswinkel-Mooy</surname><given-names>PD</given-names></name><name><surname>van Karnebeek</surname><given-names>CD</given-names></name><name><surname>van Ommen</surname><given-names>GJ</given-names></name><name><surname>van Haeringen</surname><given-names>A</given-names></name><name><surname>Rubinstein</surname><given-names>JH</given-names></name><name><surname>Saal</surname><given-names>HM</given-names></name><name><surname>Hennekam</surname><given-names>RC</given-names></name><name><surname>Peters</surname><given-names>DJ</given-names></name><name><surname>Breuning</surname><given-names>MH</given-names></name></person-group><article-title>Diagnostic analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations</article-title><source>J Med Genet</source><year>2000</year><volume>37</volume><fpage>168</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">10699051</pub-id><pub-id pub-id-type="doi">10.1136/jmg.37.3.168</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Breuning</surname><given-names>MH</given-names></name><name><surname>Dauwerse</surname><given-names>HG</given-names></name><name><surname>Fugazza</surname><given-names>G</given-names></name><name><surname>Saris</surname><given-names>JJ</given-names></name><name><surname>Spruit</surname><given-names>L</given-names></name><name><surname>Wijnen</surname><given-names>H</given-names></name><name><surname>Tommerup</surname><given-names>N</given-names></name><name><surname>van der Hagen</surname><given-names>CB</given-names></name><name><surname>Imaizumi</surname><given-names>K</given-names></name><name><surname>Kuroki</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Rubinstein-Taybi syndrome caused by submicroscopic deletions within 16p13.3</article-title><source>Am J Hum Genet</source><year>1993</year><volume>52</volume><fpage>249</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">8430691</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coupry</surname><given-names>I</given-names></name><name><surname>Monnet</surname><given-names>L</given-names></name><name><surname>Attia</surname><given-names>AA</given-names></name><name><surname>Taine</surname><given-names>L</given-names></name><name><surname>Lacombe</surname><given-names>D</given-names></name><name><surname>Arveiler</surname><given-names>B</given-names></name></person-group><article-title>Analysis of <italic>CBP </italic>(<italic>CREBBP</italic>) gene deletions in Rubinstein-Taybi syndrome patients using real-time quantitative PCR</article-title><source>Hum Mutat</source><year>2004</year><volume>23</volume><fpage>278</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">14974086</pub-id><pub-id pub-id-type="doi">10.1002/humu.20001</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vizmanos</surname><given-names>JL</given-names></name><name><surname>Larrayoz</surname><given-names>MJ</given-names></name><name><surname>Lahortiga</surname><given-names>I</given-names></name><name><surname>Floristan</surname><given-names>F</given-names></name><name><surname>Alvarez</surname><given-names>C</given-names></name><name><surname>Odero</surname><given-names>MD</given-names></name><name><surname>Novo</surname><given-names>FJ</given-names></name><name><surname>Calasanz</surname><given-names>MJ</given-names></name></person-group><article-title>t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia</article-title><source>Genes Chromosomes Cancer</source><year>2003</year><volume>36</volume><fpage>402</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12619164</pub-id><pub-id pub-id-type="doi">10.1002/gcc.10174</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name><name><surname>Strehl</surname><given-names>S</given-names></name><name><surname>Thaler</surname><given-names>D</given-names></name><name><surname>Strunk</surname><given-names>D</given-names></name><name><surname>Sill</surname><given-names>H</given-names></name><name><surname>Linkesch</surname><given-names>W</given-names></name><name><surname>Jager</surname><given-names>U</given-names></name><name><surname>Sperr</surname><given-names>W</given-names></name><name><surname>Greinix</surname><given-names>HT</given-names></name><name><surname>Konig</surname><given-names>M</given-names></name><name><surname>Emberger</surname><given-names>W</given-names></name><name><surname>Haas</surname><given-names>OA</given-names></name></person-group><article-title>RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications</article-title><source>Leukemia</source><year>2004</year><volume>18</volume><fpage>1115</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">15085163</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2403353</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rozman</surname><given-names>M</given-names></name><name><surname>Camos</surname><given-names>M</given-names></name><name><surname>Colomer</surname><given-names>D</given-names></name><name><surname>Villamor</surname><given-names>N</given-names></name><name><surname>Esteve</surname><given-names>J</given-names></name><name><surname>Costa</surname><given-names>D</given-names></name><name><surname>Carrio</surname><given-names>A</given-names></name><name><surname>Aymerich</surname><given-names>M</given-names></name><name><surname>Aguilar</surname><given-names>JL</given-names></name><name><surname>Domingo</surname><given-names>A</given-names></name><name><surname>Sole</surname><given-names>F</given-names></name><name><surname>Gomis</surname><given-names>F</given-names></name><name><surname>Florensa</surname><given-names>L</given-names></name><name><surname>Montserrat</surname><given-names>E</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name></person-group><article-title>Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation</article-title><source>Genes Chromosomes Cancer</source><year>2004</year><volume>40</volume><fpage>140</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15101047</pub-id><pub-id pub-id-type="doi">10.1002/gcc.20022</pub-id></citation></ref><ref id="B31"><citation citation-type="other"><article-title>Genbank</article-title><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/Genbank/"/></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamei</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Heinzel</surname><given-names>T</given-names></name><name><surname>Torchia</surname><given-names>J</given-names></name><name><surname>Kurokawa</surname><given-names>R</given-names></name><name><surname>Gloss</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Heyman</surname><given-names>RA</given-names></name><name><surname>Rose</surname><given-names>DW</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name><name><surname>Rosenfeld</surname><given-names>MG</given-names></name></person-group><article-title>A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors</article-title><source>Cell</source><year>1996</year><volume>85</volume><fpage>403</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">8616895</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81118-6</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Shridhar</surname><given-names>V</given-names></name><name><surname>van Deursen</surname><given-names>J</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name></person-group><article-title>CBP truncating mutations in ovarian cancer</article-title><source>J Med Genet</source><year>1996</year><volume>42</volume><fpage>514</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15937088</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2004.025080</pub-id></citation></ref><ref id="B34"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Bartsch</surname><given-names>O</given-names></name><name><surname>Rasi</surname><given-names>S</given-names></name><name><surname>Delicado</surname><given-names>A</given-names></name><name><surname>Dyack</surname><given-names>S</given-names></name><name><surname>Neumann</surname><given-names>LM</given-names></name><name><surname>Seemanova</surname><given-names>E</given-names></name><name><surname>Volleth</surname><given-names>M</given-names></name><name><surname>Haaf</surname><given-names>T</given-names></name><name><surname>Kalscheuer</surname><given-names>VM</given-names></name></person-group><article-title>Evidence for a new contiguous gene syndrome, the chromosome 16p13.3 deletion syndrome alias severe Rubinstein-Taybi syndrome</article-title><source>Hum Genet</source><comment>2006, Jun 17</comment></citation></ref></ref-list></back></article> 